In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: Good activity in leukemic relapses

Neoplasma

Volumn 52, Issue 1, 2005, Pages 74-78

  Styczynski, J ^a   Wysocki, M ^a   Debski, R ^a   Czyzewski, K ^a   Balwierz, W ^b   Juraszewska, E ^b   Matysiak, M ^c   Malinowska, I ^c   Stanczak, E ^c   Sonta Jakimczyk, D ^d   Szczepanski, T ^d   Wachowiak, J ^e   Konatkowska, B ^e   Balcerska, A ^f   Ploszynska, A ^f   Kowalczyk, J ^g   Stefaniak, J ^g   Badowska, W ^h   Wieczorek, M ^h   Olejnik, I ^h   Krawczuk Rybak, M ⁱ   Kuzmicz, M ⁱ   more..

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^h Pediatric and Oncological Hospital in Chorzów   (Poland)

ⁱ MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Leukemia; Nucleoside analogues; Resistance; Sensitivity

Indexed keywords

CLADRIBINE; CYTARABINE; FLUDARABINE PHOSPHATE; NUCLEOSIDE ANALOG;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; LEUKEMIA; LEUKEMIA CELL; MALE; NEWBORN; PROTEIN SYNTHESIS; RELAPSE; RNA SYNTHESIS;

EID: 20044384710     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. GANDHI V, ESTEY EE, SEYMOUR JF, SAMPATH D, DU M et al. Modulation od AraC metabolism to improve AML response. In: Hiddemann W. editor. Acute Leukemias VII. Experimental Approaches and Novel Therapies. Springer-Verlag, Berlin, Heidelberg, 1998:577-583.
2. KANO Y, AKUTSU M, TSUNODA S, SUZUKI K, ICHIKAWA A et al. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia 2000; 14: 379-388.
3. KANTARJIAN H, GANDHI V, CORTES J, VERSTOVSEK s, DU M et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379-2386.
4. KASPERS GJL, VEERMAN AJP, PIETERS R, BROEKEMA GJ, HUISMANS DR et al. Mononuclear cells contaminating leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 1994; 70: 1047-1052.
5. MONTILLO M, MIRTO S, PETTI MC, LATAGLIATA R, MAGRIN S et al. Fludarabine, Cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998; 58: 105-109.
6. PARKER WB, SHADDIX SC, ROSE LM, SHEWACH DS, HERTEL LW et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl) adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999; 55: 515-520.
7. STYCZYNSKI J, PIETERS R, HUISMANS DR, SCHUURHUIS GJ, WYSOCKI M, VEERMAN AJP. In vitro drug resistance profiles in adult versus childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 813-818.
8. STYCZYNSKI J, WYSOCKI M, BALWIERZ W, ROKICKA-MILEWSKA R, MATYSIAK M et al. In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia. Neoplasma 2002; 49: 178-183.
9. STYCZYNSKI J, WYSOCKI M, DEBSKI R, JURASZEWSKA E, MALINOWSKA I et al. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia. Leuk Lymphoma 2002; 43: 1843-1848
10. SZMIGIELSKA-KAPLON A, ROBAK T. Immunosuppressive activity of new purine analogues. Acta Haematol Pol 2001; 32: 243-254.
11. WYSOCKI M, STYCZYNSKI J, DEBSKI R, KUBICKA M, BALWIERZ W et al. Drug resistance profile in childhood acute lymphoblastic leukemia on diagnosis and at relapse with respect to percentile values. Report of Polish Pediatric Leukemia and Lymphoma Study Group. Acta Haematol Pol 2002; 33: 341-350.